Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure